78 related articles for article (PubMed ID: 23288644)
21. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.
Chen R; Ravindra VM; Cohen AL; Jensen RL; Salzman KL; Prescot AP; Colman H
Neurosurg Focus; 2015 Mar; 38(3):E2. PubMed ID: 25727224
[TBL] [Abstract][Full Text] [Related]
22. The hypermethylation of the O6-methylguanine-DNA methyltransferase gene promoter in gliomas--correlation with array comparative genome hybridization results and IDH1 mutation.
Tuononen K; Tynninen O; Sarhadi VK; Tyybäkinoja A; Lindlöf M; Antikainen M; Näpänkangas J; Hirvonen A; Mäenpää H; Paetau A; Knuutila S
Genes Chromosomes Cancer; 2012 Jan; 51(1):20-9. PubMed ID: 21922591
[TBL] [Abstract][Full Text] [Related]
23. Adult grade II diffuse astrocytomas are genetically distinct from and more aggressive than their paediatric counterparts.
Jones DT; Mulholland SA; Pearson DM; Malley DS; Openshaw SW; Lambert SR; Liu L; Bäcklund LM; Ichimura K; Collins VP
Acta Neuropathol; 2011 Jun; 121(6):753-61. PubMed ID: 21327941
[TBL] [Abstract][Full Text] [Related]
24. Polar spongioblastoma: A high-grade glioma that does not contain the IDH1 mutation or 1p/19q LOH.
Nagaishi M; Tanaka Y; Iwatate K; Yokoo H; Ueki K; Hyodo A; Nakazato Y
Neuropathology; 2010 Oct; 30(5):547-52. PubMed ID: 20102524
[TBL] [Abstract][Full Text] [Related]
25. Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades.
Lavon I; Refael M; Zelikovitch B; Shalom E; Siegal T
Neuro Oncol; 2010 Feb; 12(2):173-80. PubMed ID: 20150384
[TBL] [Abstract][Full Text] [Related]
26. Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying).
Ostrom QT; Gittleman H; Kruchko C; Louis DN; Brat DJ; Gilbert MR; Petkov VI; Barnholtz-Sloan JS
J Neurooncol; 2016 Oct; 130(1):31-42. PubMed ID: 27418206
[TBL] [Abstract][Full Text] [Related]
27. Perspectives of Personalized Chemotherapy of Gliomas Based on Molecular Tumor Profiling.
Soffietti R; Franchino F; Magistrello M; Pellerino A; Rudà R
Prog Neurol Surg; 2018; 31():168-179. PubMed ID: 29393185
[TBL] [Abstract][Full Text] [Related]
28. Genetic and epigenetic alterations in primary-progressive paired oligodendroglial tumors.
Kuo LT; Tsai SY; Chang CC; Kuo KT; Huang AP; Tsai JC; Tseng HM; Kuo MF; Tu YK
PLoS One; 2013; 8(6):e67139. PubMed ID: 23826216
[TBL] [Abstract][Full Text] [Related]
29. [The role of the pathologist in the diagnosis and therapy planning of central nervous system tumors. Prognostic and predictive markers].
Turányi E; Hanzély Z; Bálint K; Reiniger L
Magy Onkol; 2013 Dec; 57(4):215-21. PubMed ID: 24353986
[TBL] [Abstract][Full Text] [Related]
30. Actionable molecular biomarkers in primary brain tumors.
Staedtke V; Dzaye O; Holdhoff M
Trends Cancer; 2016 Jul; 2(7):338-349. PubMed ID: 28603776
[TBL] [Abstract][Full Text] [Related]
31. Gene markers in brain tumors: what the epileptologist should know.
Ostrom Q; Cohen ML; Ondracek A; Sloan A; Barnholtz-Sloan J
Epilepsia; 2013 Dec; 54 Suppl 9(0 9):25-9. PubMed ID: 24328868
[TBL] [Abstract][Full Text] [Related]
32. MGMT-Methylated Alleles Are Distributed Heterogeneously Within Glioma Samples Irrespective of IDH Status and Chromosome 10q Deletion.
Fontana L; Tabano S; Bonaparte E; Marfia G; Pesenti C; Falcone R; Augello C; Carlessi N; Silipigni R; Guerneri S; Campanella R; Caroli M; Sirchia SM; Bosari S; Miozzo M
J Neuropathol Exp Neurol; 2016 Aug; 75(8):791-800. PubMed ID: 27346749
[TBL] [Abstract][Full Text] [Related]
33. [Molecular background of the melanoma and the brain metastasis].
Katona F; Murnyák B; Marko-Varga G; Hortobágyi T
Orv Hetil; 2017 Jul; 158(28):1083-1091. PubMed ID: 28691878
[TBL] [Abstract][Full Text] [Related]
34. Prognosis-related molecular markers in pediatric central nervous system tumors.
Rickert CH
J Neuropathol Exp Neurol; 2004 Dec; 63(12):1211-24. PubMed ID: 15624758
[TBL] [Abstract][Full Text] [Related]
35. Clinical neuropathology practice guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers.
Berghoff AS; Stefanits H; Woehrer A; Heinzl H; Preusser M; Hainfellner JA;
Clin Neuropathol; 2013; 32(3):148-58. PubMed ID: 23618424
[TBL] [Abstract][Full Text] [Related]
36. Organ Specific Tumor Markers: What's New?
Vaidyanathan K; Vasudevan DM
Indian J Clin Biochem; 2012 Apr; 27(2):110-20. PubMed ID: 23542399
[TBL] [Abstract][Full Text] [Related]
37. Genetic markers: not yet ready for prime time.
Butterworth J
Anesthesiology; 2004 Feb; 100(2):458; author reply 458-9. PubMed ID: 14739832
[No Abstract] [Full Text] [Related]
38. Prognostic molecular testing in melanoma: ready for prime time?
Keller J; Diggs LP; Hsueh EC
Melanoma Manag; 2017 Dec; 4(4):171-174. PubMed ID: 30190922
[No Abstract] [Full Text] [Related]
39. Glioma biology and molecular markers.
Cohen AL; Colman H
Cancer Treat Res; 2015; 163():15-30. PubMed ID: 25468223
[TBL] [Abstract][Full Text] [Related]
40. A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells
El-Soussi S; Hanna R; Semaan H; Khater AR; Abdallah J; Abou-Kheir W; Abou-Antoun T
Front Pediatr; 2021; 9():693145. PubMed ID: 34422720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
